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UDP-glucose dehydrogenase (UGDH) supplies the cell with
UDP-glucuronic acid (UDP-GlcUA), a precursor of glycosamino-
glycan and proteoglycan synthesis. Here we reported the cloning
and the characterization of theUGDH from the amphibianXenopus
laevis that is one of themodel organisms for developmental biology.
We found that X. laevis UGDH (xUGDH) maintained a very high
degree of similarity with other knownUGDH sequences both at the
genomic and the protein levels. Also its kinetic parameters are sim-
ilar to those of UGDH from other species. During X. laevis develop-
ment, UDGH is always expressed but clearly increases its mRNA
levels at the tail bud stage (i.e.30hpost-fertilization). This result fits
well with our previous observation that hyaluronan, a glycosamin-
oglycan that is synthesized using UDP-GlcUA and UDP-N-acetyl-
glucosamine, is abundantly detected at this developmental stage.
The expression of UGDH was found to be related to hyaluronan
synthesis. In human smooth muscle cells the overexpression of
xUGDH or endogenous abrogation of UGDH modulated hyaluro-
nan synthesis specifically. Our findings were confirmed by in vivo
experiments where the silencing of xUGDH in X. laevis embryos
decreased glycosaminoglycan synthesis causing severe embryonic
malformations because of a defective gastrulation process.
UDP-glucose dehydrogenase (UGDH,2 EC 1.1.1.22) catalyzes an
NAD-dependent, 2-fold oxidation of UDP-glucose (UDP-Glc) to
generate UDP-GlcUA (1). In mammals, UDP-GlcUA is used in the bio-
synthesis of hyaluronan (HA) and the glycosaminoglycans (GAGs)
heparan sulfate and chondroitin sulfate (2). In addition, it is used in the
liver where glucuronidation targets molecules for excretion (3). UDP-
GlcUAalso serves as a precursor toUDP-xylose, which provides amajor
component of the cell wall polysaccharides in plants (4), and represents
the initial sugar in GAG synthesis on proteoglycans. In many strains of
pathogenic bacteria, such as group A streptoccoci and Streptococcus
pneumoniae type 3, UDP-GlcUA is used in the construction of the
antiphagocytic capsular polysaccharide (5, 6). UGDH is of biochemical
mechanistic interest because it belongs to a family of sugar nucleotide-
modifying enzymes that catalyze a net four-electron oxidation and serve
as both alcohol dehydrogenases and aldehyde dehydrogenases (7).
The importance of UGDH is remarkable considering that its product,
UDP-GlcUA, is critical for GAG synthesis. GAG chains of proteogly-
cans and HA are ubiquitous components of extracellular matrices and
pericellular spaces, and an increasing body of information shows the
role of GAGs in cell behavior, including signal transduction, cell prolif-
eration, spreading, migration, cancer growth, and metastasis (8–10).
Proteoglycans andHA have important roles throughout the develop-
ment (11). As UGDH synthesizes UDP-GlcUA, one of the main UDP-
sugar precursors, it is not surprising that alteration inUGDHexpression
causes evident phenotypes in developing embryos, as found by different
authors in differentmodel organisms. In particular, inDrosophilamela-
nogaster UGDH is encoded by the sugarless gene and is required for
heparan sulfate modification of proteins that control wing formation
(12). In Caenorhabditis elegans, UGDH influences GAG synthesis,
which is essential for vulval morphogenesis and embryonic develop-
ment (13, 14). In Zebrafish, the enzyme is critical for normal cardiac
development (15). In mouse, UGDHmutants arrest growth during gas-
trulation with defects in migration of mesoderm and endoderm (16).
Moreover, a similar phenotype was found in mutants in the fibroblast
growth factor pathway, highlighting that proteoglycans andGAGs facil-
itate signaling by mammalian growth factors.
Another well known model organism extensively used in develop-
mental biology is the amphibian Xenopus laevis. Although several
papers report the critical role of proteoglycans in X. laevis development
(17–22), very limited information is available on GAG functions in
amphibian embryogenesis (23–25). Therefore, we have characterized
the X. laevisUGDH (xUGDH), the key enzyme in GAG biosynthesis in
this model organism, as suitable for developmental studies. Here we
report the cDNA cloning of xUGDH, its biochemical kinetic parame-
ters, its expression in developing embryos, and its genome organization.
We have also extended our observations to Xenopus tropicalis, an orga-
nism of the same genus as X. laevis, but with interesting potential for
genetic studies (26). Our results show that the xUGDH expression in
human cells increases their HA accumulation (and not that of other
GAGs), whereas UGDH abrogation by siRNA reduced HA synthesis
and cell-associated GAGs. Moreover, we have also demonstrated that
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UGDHhas a crucial role duringX. laevis development because xUGDH
loss of function, by morpholino injection, causes lethal malformation.
MATERIALS ANDMETHODS
xUGDH Cloning—An X. laevis EST data bank was searched for
homologies with humanUGDH cDNA (GenBankTM accession number
NM_003359) using the World Wide Web-based BLAST search engine
(www.ncbi.nlm.nih.gov/blast/). IMAGE EST number 4202110 was
found andwas obtained fromMRCgeneservice (Cambridge, UK). DNA
sequencing was done by an external service facility (BMR, Padua, Italy).
Characterization of the xUGDH Gene—Introns of the X. laevis
xUGDH gene were amplified with a pair of primers (Table 1) designed
on the basis of mouse and humanUGDH genomic sequences deposited
in public data bases. PCR parameters were as follows: denaturation at
94 °C for 30 s, annealing for 30 s at the temperature indicated in Table 1,
and elongation at 72 °C for 5min for 35 cycles using 1.5 units of La-TAQ
(a proofreading DNA polymerase from Takara) following the manufac-
turer’s conditions. Amplification of intron 8 was done using PhusionTM
polymerase (Finnzymes) in 6% Me2SO. PCRs were done on genomic
DNA. Amplified intron lengths were determined by gel electrophoresis,
and exon/intron boundaries were determined by sequencing the
extracted bands from the gels.
In silico determinations of the intron/exon structure of the human,
mouse, andX. tropicalis UGDH genes were done by BLAST searches on
the genomic data bases. Sequence manipulations and contig construc-
tions were done using Vector NTI Suite 6 software.
Recombinant xUGDH Expression and Purification—Cloning and
transformation techniques were done essentially as described by Sam-
brook et al. (27). A histidine-tagged xUGDHconstructwas generated by
PCR. Briefly, the xUGDH ORF was amplified using Phusion DNA
polymerase (Finnzymes) with the following primers: CCAAGGCTC-
GAGATGTTTCAGATTAAGAAGATTT and CCTTGGCTCGAGT-
TAAACTCTTTGTTTCTTATGAGGC (the sequences corresponding
to XhoI recognition sites are underlined). The amplified product was
digested with XhoI (Takara) and cloned into the XhoI-linearized pET-
19b (Novagen) plasmid. This construct (pHisxUGDH) was then
sequenced; it encodes the full-length xUGDH protein with an addi-
tional His6 tag sequence at the N terminus.
For protein expression, the plasmid pHisxUGDH was transferred to
the host BL21(DE3)pLysS E. coli strain (Promega). E. coli cells carrying
the recombinant plasmid were cultivated at 37 °C in LB medium con-
taining ampicillin and chloramphenicol (100 and 34 g/ml final con-
centrations, respectively). After an overnight growth (A600 nm 2.5),
IPTG was added at a final concentration of 1 mM. The temperature was
reduced to 30 °C, and the cells were collected after 24 h. Cell extraction
and His-tagged xUGDH purification were done using the B-Ter purifi-
cation kit (Pierce) following the manufacturer’s instructions. Some
determinations were done on crude extracts that were prepared lysing
the bacterial cells in B-Ter solution (Pierce) and recovering the super-
natant after centrifugation.
xUGDH Assay—The enzymatic activity of purified His-tagged
xUGDH was determined by monitoring the change in absorbance at
340 nm that accompanies reduction of NAD to NADH. The assay
conditions were the same as those described previously by Sommer
et al. (28).
Gene Expression Studies—Total RNA from 21 X. laevis embryos (7
from three different females) at different stages of development were
extracted using Trizol reagent (Invitrogen) following the manufactur-
er’s protocol. One g of total RNA from each extract was retrotrans-
cribed using 200 units of Moloney murine leukemia virus reverse tran-
scriptase (Invitrogen) and a (dT)16 primer at a concentration of 500
g/ml. The reaction was done in 50mMTris-HCl, pH 8.3, 75mMKCl, 3
mM MgCl2, 10 mM dithiothreitol, and 500 M of a dNTP mixture at
42 °C for 50 min. PCR amplifications of the cDNA samples were done
using the first strand cDNA synthesismixture, 25 pmol of primer xUGDH
upper primer (CCCTTTGTGAGGCTACAGGA) and xUGDH lower
primer (CGGTGCAGATAACCATAGCA), 200MdNTPs, and 1 unit of
RedTaq polymerase (Sigma) in its own buffer. Reaction mixtures were
subjected to eight touchdown cycles with annealing temperatures from
58 to 54 °C and subsequently with cycles using the following parame-
ters: denaturation at 94 °C for 30 s, annealing at 53 °C for 30 s, and
elongation at 72 °C for 40 s. As a control for genomic DNA contamina-
tion, all reactions were established with the control sample lacking
reverse transcriptase. Normalization was done detecting cytoskeletal
actin (upper primer, CTGAGTTCATGAAGGATCAC; lower primer,
AAATTTACAGGTGTACCTGC) (29) with the above described
conditions.
Quantitative real time RT-PCR was used in transfection experiments
with aortic smoothmuscle cells (AoSMC) (see below). Forty eight hours
after transfections, total RNA samples were extracted with Trizol
(Invitrogen) and retrotranscribed using the High Capacity cDNA syn-
thesis kit (Applied Biosystems) for 2 h at 37 °C. Quantitative RT-PCR
was performed on an ABi Prism 7000 instrument (Applied Biosystems)
using the Taqman Universal PCR Master Mix (Applied Biosystems)
following the manufacturer’s instructions. Probe and primers were
developed from TaqMan gene expression assay reagents (Applied
Biosystems). The following human TaqMan gene expression assays
were used: HAS1 (Hs00155410_m1), HAS2 (Hs00193435_m1),
HAS3 (Hs00193436_m1), UGDH (Hs00163365_m1), and -actin
(Hs99999993_m1). Fluorescent signals generated during PCR amplifi-
cations were monitored and analyzed with ABi Prism 7000 SDS soft-
ware (Applied Biosystems). Comparisons of the amounts of each gene
transcript among different samples were made using -actin as a refer-
ence. Standard curves were generated by serial dilution of cDNA, and as
calculations of PCR efficiency were very similar (about 90%) for each
gene assayed, the relative quantitative evaluation of target gene levels
was determined by comparing Ct (Applied Biosystems user bulletin
number 2).
xUGDH Expression in Mammalian Cells—The xUGDH ORF was
amplified using PhusionTM DNA polymerase (Finnzymes) with the
following primers: TACTCGAGACCATGTTTCAGATTAAGAA-
GATTT and ATCTCGAGTTAAACTCTTTGTTTCTTATGAGGC.
The boldface sequences correspond to XhoI recognition sites, and the
underlined adenosine represents the typical 3 purine of the Kozak
consensus sequence. The amplified product was purified, A-tailed using
RedTaq (Sigma), and cloned into a pTarget (Promega) vector. Expres-
sion plasmids were selected to have the insert in the sense orientation to
synthesize the complete xUGDHprotein (pTarget-xUGDH sense) or to
have the insert in the opposite direction used as the control vector
(pTarget-xUGDH antisense). DNA sequencing and in vitro transcrip-
tion and translation (TNT in vitro transcription/translation system, Pro-
mega) were done to check the constructs. AoSMCs (Cambrex) were
grown in SmGm2 complete (supplemented with 5% fetal bovine serum)
culture medium (Cambrex). The cultures were maintained in an atmo-
sphere of humidified 95% air, 5% CO2 at 37 °C. 1  106 cells between
passages 2 and 5 were transiently transfected by means of a Nucleofec-
tor apparatus (Amaxa) and the human aortic smooth muscle cells
NucleofectorTM kit using 5 g of either the sense or antisense expres-
sion plasmid. After 48 h, transfected cells and conditioned cell culture
media were collected. Cells were lysed in 50 mM Tris-HCl, pH 7.4, 150
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mM NaCl, 1% Triton X-100 supplemented with a protease inhibition
mixture (Roche Applied Science) using a cell scraper. Protein contents
in the cell lysates were determined using the Bradford method, and
UGDH activities were measured as described above.
Abrogation of Human UGDH—siRNA was used to reduce human
UGDH expression in AoSMCs. UGDH siRNA (5-GGACUAAAA-
GAAGUGGUAGGtt-3) and negative control siRNA 1 kit (scramble,
code 4611) were purchased from Ambion. Transfections were done
using a Nucleofector apparatus (Amaxa) and the human AoSMC
NucleofectorTM kit using an siRNA concentration of 50 M of either
UGDHsiRNAor scramble siRNA.After 48 h of incubation, conditioned
cell media were assayed for GAG contents by FACE analysis. The trans-
fected cells were used for determination of UDP-sugars contents and
UGDH activities. Quantitative real time RT-PCR was used to verify the
reduction of UGDH mRNA expression.
GAG Disaccharides and UDP-sugar Precursor Determinations—HA
and chondroitin sulfate disaccharides were determined by FACE anal-
ysis as described previously (30). UDP-Glc andUDP-GlcUAwere quan-
tified by capillary zone electrophoresis using the methodology outlined
by Lehmann et al. (31). Briefly, 106 AoSMCs were lysed in 0.1 ml of
phosphate-buffered saline containing 0.5% Triton X-100. After centrif-
ugation, the supernatants were deproteinized by acetonitrile treatment,
lyophilized, and resuspended in 90 mM borate buffer, pH 9. Analyses
were done using a 75 cm 50mcolumn, 25-kV voltage, and detecting
UDP-sugar absorbances at 262 nm. The peak identity was assessed by
co-injecting the extracts with commercial UDP-Glc and UDP-GlcUA.
GAG Determinations—To evaluate the amount of each GAG after
induction or abrogation of UGDH, AoSMCs were transfected with
pTarget-xUGDH constructs or siRNA, respectively, and labeled with
[3H]glucosamine (25 Ci/ml) for 48 h in complete SmGm2 medium.
Conditioned cell medium was recovered, and the unincorporated
[3H]glucosamine was removed by gel filtration using a PD10 column
(Amersham Biosciences). The cell layer was washed with phosphate-
buffered saline and scraped into 100 l of phosphate-buffered saline
containing 1% Triton X-100, centrifuged at 10,000  g for 10 min at
4 °C. The clear supernatant and the PD10 filtrated medium were
digestedwith proteinaseK (Finnzymes) at 50 °C. After 8 h of incubation,
proteinase K was inactivated at 90 °C for 10 min. Each GAG solution
was separated into 4 aliquots, precipitated by adding 4 volumes of eth-
anol at20 °C for 18 h, and recovered by centrifugation. Two aliquots
were resuspended in 0.1 M ammonium acetate, pH 7, and digested with
100 milliunits/ml of hyaluronidase SD from Streptococcus dysgalactiae
(Seikagaku) and 100 milliunits/ml of chondroitinase ABC (Seikagaku),
respectively; one was resuspended in 10 mM Tris-HCl, pH 7, 4 mM
CaCl2 and digested with 100 milliunits/ml of heparanase I, II, and III
(Seikagaku). The last aliquot was used as an undigested control. After
16 h of incubation at 37 °C, which allow complete degradation of 20
g/ml of standard GAGs, 50 g of chondroitin sulfate A (Seikagaku)
was added to each digested sample as carrier, and undigested GAGs
were precipitated with ethanol. Specific GAGs were quantified by
counting the radioactivity associated with digestion products (in the
supernatant) and the undigested GAGs (pellet) with a liquid scintilla-
tion counter (Canberra Packard).
xUGDH Silencing during X. laevis Development—Two antisense
morpholino-oligonucleotides (MOs; Gene Tools LLC) were generated
on the basis of the xUGDH cDNA sequence, xUGDHMO CATGGT-
TTATCTTGCTGAGAACAGA, which is complementary to the
xUGDH translation start site and the adjacent coding sequence. A
5-mismatch MO, based on the xUGDH MO sequence, was used as a
specificity control (CATcGTTTATgTTGgTGAcAAgAGA, where
lowercase letters indicate mismatched nucleotides). The optimal mor-
pholino concentration to inject per embryo was established by inde-
pendent pilot experiments (not shown) and was determined to be in the
range of 10–20 ng/embryo. The MOs were injected bilaterally at the
two-cell stage to down-regulate the xUGDH activity in the whole
embryo. All the experiments were performed by co-injecting the mor-
pholino-oligonucleotide and the GFP mRNA (300 pg/embryo) as a
tracer in order to select only the properly manipulated embryos for the
subsequent analysis. Embryos were injected in 0.1 Modified Marc’s
Ringer solution (MMR) (100mMNaCl, 1.8 mMKCl, 1 mMMgCl2, 2 mM
CaCl2, 5 mM HEPES, pH 7.8) supplemented with 4% Ficoll and then
cultured in 0.1MMR solution until the stage of analysis.
RESULTS ANDDISCUSSION
xUGDH cDNA Cloning—In this study we focused our attention on
UGDH, a pivotal enzyme in the production of UDP-GlcUA, an impor-
tant precursor for GAG synthesis. It has been reported that UGDH is
crucial in C. elegans and D. melanogaster morphogenesis (12, 13) and
Zebrafish cardiac valve formation (15) and is also involved in mouse
gastrulation (16). We reported previously the characterization of HA
synthases (HAS1, HAS2, and HAS3) in X. laevis and showed their reg-
ulation during the early stages of development (34, 35). It is also possible
that UGDH, which provides one of the substrates for HAS, is regulated
in the embryogenesis of this species. Therefore, we decided to clone
X. laevis UGDH and characterize it.
To obtain the sequence of the xUGDHmRNA,we initially performed
a BLAST search using the human UGDH sequence against an X. laevis
EST data base. This revealed several ESTs with a high degree of identity
with the human sequences. We then obtained the largest EST (dbEST
code 4202110) fromMRC geneservice (Cambridge, UK); we completed
the sequence and deposited in the public data base with GenBankTM
accession number AY762616 (data not shown). This sequence has a
42-bp-long 5-UTR and a 1482-bp-long ORF coding for a protein with
494 amino acids, a calculated molecular mass of 55,209.4 Da, and a
calculated isoelectric point of 6.49. A PROSITE analysis (www.expasy.org/
prosite/) and a NetPhos analysis (www.cbs.dtu.dk/services/NetPhos/) of
the xUGDH amino acid sequence revealed several putative phosphoryla-
tion sites. Although we did not further investigate the possibility of post-
translation modifications in this enzyme, previous studies have reported
that UGDHmay be phosphorylated in prokaryotic cells (36, 37).
We searched for known signal peptides using the PSORT II program
(www.psort.org/) without identifying any sorting sequence. xUGDH
localization was predicted to be cytoplasmic with a 65.2% probability.
Such a localization is consistent with a previous report that placed
UGDH in the cytosol (13).
The deduced amino acid sequences of xUGDH and other known
UGDH from several species are aligned (data not shown). The N-ter-
minal region has the consensus sequence for NAD binding (i.e.
GXGXXG) that is maintained with a high degree of identity among
all the UGDH analyzed. The central region of the protein (i.e.
GFGGSCFQKDVLN) has been proposed to be the catalytic domain
(38), and all the aligned sequences show a high degree of identity
with only a minor amino acid substitution in the UGDH belonging to
C. elegans, D. melanogaster, and soybean. Moreover, the critical cys-
teine residue, number 276 of xUGDH, is conserved in all sequences,
and it has been shown to be involved during the second half-reaction
of UGDH (i.e. conversion of UDP-aldehydroglucose to UDP-GlcUA)
(28). With respect to function/structure considerations, proline res-
idues at positions 92 and 160 are believed to represent main bends in
the protein structure (39–41), and they are conserved for UGDH
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from all species. Two lysine residues at positions 220 and 339 are also
conserved, which correspond to lysine 219 and 338 of bovine UGDH.
One of these lysine residues is probably catalytically involved in the
first half-reaction of the enzyme (i.e. conversion of UDP-Glc to
UDP-aldehydoglucose) (39, 42). Moreover, using Conseq analysis
(freely available at the Internet site conseq.bioinfo.tau.ac.il/) (43),
regions spanning from amino acids 41–54, 128–135, 340–350, and
461–464 have been identified as important for the structure or func-
tion of the protein (results not shown). Although this analysis is only
a virtual prediction, it was done on all the known UGDH sequences
deposited in the data bases. Such regions could be useful to under-
stand not only the catalytic mechanism of the reaction but also to
identify critical residues involved in a hypothetical regulatory mech-
anism that a pivotal enzyme such as UGDH could possess. Recently,
for example, Conseq analysis has been successfully used to isolate
important regions for protein-protein interactions (44).
Genomic Organization of xUGDH—By comparing the xUGDH tran-
script to the human and mouse genomic sequences available in public
data bases, we have inferred the positions of the introns of the xUGDH
gene. For each hypothetical intron, we have designed, on the two flank-
ing exons, a pair of specific primers (Table 1) to amplify by long ampli-
fication PCR a region expected to contain the intron. PCR products
were separated by gel electrophoresis, and the exon-intron junctions
were sequenced. As reported in Table 2, top and bottom portions, the
structure of the xUGDH gene is composed of 11 exons and 10 introns,
and it matches that of mammalian UGDH genes (45). Notably, in the
5-untranslated region of the human andmouse UGDHmRNA, we and
others (45) found an additional intron of about 5700 bp. As this intron is
located far upstream from the ATG start codon, we did not further
investigate its position in the xUGDH gene. The major variability was
detected in intron lengths, although all of them conserve their intron
phase, indicating that the intron insertion points in the cDNA sequence
have remained constant during xUGDH gene evolution. Most interest-
ingly, the consensus gt-ag (5–3) splice site sequences are not always
conserved in the xUGDH gene as shown in the 5 splice acceptor
sequence of intron 5. However, this noncanonical splice site has been
reported to be quite frequent and does not cause any deleterious muta-
tions (46, 47). Moreover, this noncanonical splice site may be the main
5 intron acceptor site used during embryogenesis. In fact, no alterna-
tive splice isoforms of xUGDH transcripts have been found during
X. laevis development by RT-PCRusing two primers (i.e. xUGDHupper
primer and xUGDH lower primer) flanking the intron 5 insertion point
in the cDNA sequence.
X. laevis is certainly a well recognized “model organism” for cell and
developmental biology, but it has the disadvantage of being tetraploid,
which greatly complicates the creation of mutants and the analysis of
gene regulation. In contrast, X. tropicalis, an amphibian of the same
genus, is diploid and possesses a relatively small genome, whose
sequencing is currently in progress. Therefore, X. tropicalis is destined
to complement X. laevis as a model organism (26). Thanks to available
preliminary data on the X. tropicalis genome (www.genome.jgipsf.org),
we have determined the X. tropicalis UGDH genomic organization
(Table 2, bottom portion), and as expected, the two genes are indeed
very similar.
Recombinant xUGDH Expression and Characterization—To study
the biochemical properties of xUGDH, we have generated the pHisx-
UGDH plasmid that codes for a His6-tagged xUGDH. This plasmid was
used to transform Escherichia coli BL21(DE3)pLysS cells, and the
recombinant protein expression was induced by IPTG treatment.
Experiments were done to optimize the expression conditions, analyz-
ing the effect of temperature, time of induction and collection, and
IPTG concentration on xUGDH expression. The best conditions were
obtained using E. coli cells grown overnight at 37 °C, inducedwith 1mM
IPTG, cultured at 30 °C, and harvested 24 h after induction. The recom-
binant xUGDH overexpressed under these conditions was completely
soluble and thus fully recovered in the crude extract. The specific
UGDH activity in the crude extract of induced E. coli BL21(DE3)pLysS
was about 50-fold higher than that of crude extracts of uninduced cells
(data not shown).
The crude extract from IPTG-induced E. coli cells was affinity-puri-
fied using a commercial spin column kit (Pierce). After the three elution
steps suggested by the manufacturer, recombinant His-tagged xUGDH
was eluted as a nearly single resolved band, and the final preparationwas
at least 90% homogeneous as judged by SDS-PAGE analysis (result not
shown). The 54-kDa band corresponding to recombinant His-tagged
xUGDH is in agreement with the molecular weight theoretically calcu-
lated from the translated xUGDH cDNA sequence. After the affinity
chromatography step, the specific activity increased about 12-fold (data
not shown).
As UGDH reduces twomolecules of NAD to NADH during the con-
version of a UDP-Glc substrate to a UDP-GlcUA, we followed the reac-
tion by measuring NADH absorbance at 340 nm. To obtain kinetic
TABLE 1
Sequence of the primers used in this work to amplify the indicated intron
Intron Primer Sequence 5–3 Annealing temperature°C
Intron 1 XEso1_up CGTGATTGCCCAAATGTGTC 53
XEso2_low CAGCTTCCTGTATAGCTCCGTCT
Intron 2 XEso2_up GCCGAGGCAAGAATCTGTTT 52
XEso3_low ATCAAATATCCGCCGAATGC
Intron 3 XEso3_up TGCCAGAAGGATTGTCCAAA 53
XEso4_low TCACATAGTGCACGCACAGC
Intron 4 XEso4_up ACCGGGTGTTAATTGGTGGA 53
XEso5_low TTCCTCCACATCTGCTCCTG
Intron 5 XEso5_up ATGCTTTCCTTGCCCAGAGA 53
XEso6_low TTGCCACTTCATGCAGGTTC
Intron 6 XEso6_up GCTGTTTCCAAAAGGATGTCTTG 53
XEso7_low TGCAAAACCAAGGAGAGCAA
Intron 7 XEso7_up CAAGGATTATCGATTGCCTGTT 53
XEso8_low CCCTTGGAACTTTGGGATCA
Intron 8 XEso8_up CCTCATGGATGAAGGTGCAA 54
XEso9_low CCATTCGGTGCAGATAACCA
Intron 9 XEso9_up GCTGGTTCACATTTCTACGGATT 53
XEso10_low TATTTTGCAGCTCGCCATGA
Intron 10 XEso10_up AGAATGATGTTGAAGCCAGCA 53
XEso11_low GCAGGTCTTGCAAACCGAAT
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constants (Km and Vmax) for substrate and cofactor, we used the same
experimental buffers and conditions described previously (28). More-
over, we did not remove the His6-tagged sequence as it has been
reported that it does not alter the property of the enzyme (28). The
purified enzyme showed no reduction of NAD if incubated with either
UDP-galactose, UDP-GlcUA, or UDP-N-acetylglucosamine, indicating
the purity and specificity of the enzyme (results not shown).
The steady-state kinetic parameters ofHis-tagged xUGDHhave been
calculated by incubating the enzyme with increasing concentrations of
NAD in the presence of saturating UDP-Glc substrate (Fig. 1A). Simi-
larly, the dependence of reaction kinetics on the substratewasmeasured
by increasing UDP-Glc concentration in the presence of saturating
NAD (Fig. 1C). For both the substrates, saturation kinetics were
observed. A double-reciprocal plot of the initial velocities revealed a Km
of 0.9 mM for UDP-Glc (Fig. 1B) and a Km of 0.3 mM for NAD (Fig. 1D).
Both sets of conditions yielded a similar Vmax of about 10 nmol of
NADH/min/mg of enzyme. These data are comparable with those of
UGDH from other species (Table 3).
TABLE 2
Structure of the xUGDH gene
Top shows schematic representation of the xUGDH gene. Lines indicate introns; filled boxes indicate exons in the open reading frame; open boxes indicate exons in the 5-
and 3-UTRs. Dotted lines and box represent the exon and the intron of the human UGDH gene located in the 5-UTR (not characterized in the X. laevis gene). Bottom
shows intron sizes were determined by gel electrophoresis, and position numbering is based on exon coding sequences where A of the ATG start codon is1. Uppercase
letters are exonic sequences, and lowercase letters are intronic sequences. n.d. indicate not determined. Hs, Homo sapiens; Mm, Mus musculus; Xl, Xenopus laevis; Xt,
Xenopus tropicalis.Analyses were done on the basis of sequences AC021148 andAC108506 for human andmouse, respectively. TheX. tropicalisUGDHgenomic sequence
was derived from sequence scaffold 10698, 7440, and AASO427206.bl.
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xUGDH Expression during Development—The amphibian X. laevis
has become one of the most studied organisms in developmental biol-
ogy together with C. elegans and D. melanogaster. As no information
was available, we investigated the regulation of xUGDHduringX. laevis
development. RT-PCR was done on RNA extracted from the same
number of embryos at different developmental stages. To visualize dif-
ferences in the expression, different PCR cycles were done as outlined in
Fig. 2. Although the 531-bp-long band corresponding to the amplicon of
xUGDH was detectable in all the tested developmental stages, a more
pronounced signal was visualized in the sample from 30 h post-fertili-
zation (hpf) that corresponds to an embryo at the tail bud stage. Such an
expression pattern is related to the crucial function of UDP-GlcUA. In
fact, this molecule is a precursor for all GAGs (with the exception of
keratan sulfate), including GAGs of proteoglycans and HA that are
known to be essential for a proper development (11).Most interestingly,
the increase in xUGDH in the 30-hpf embryos corresponded with our
previous finding that HA is dramatically elevated in embryos at this
developmental stage (34). Moreover, the enzymes involved in HA syn-
thesis (i.e. HAS2 and HAS3) are also up-regulated in this embryonic
stage (34). Although the precise role of HA in X. laevis development is
still to be defined, HA is critical during embryonic development of
mammals. For example, mice unable to produce HA die in the uterus
from severe cardiac malformation (49, 50).
xUGDH Expression and HA Synthesis—The data reported in this
study strongly support the hypothesis that coordinated expression of
UGDH and HAS may have a pivotal role in regulating HA levels. To
elucidate the relationship between UGDH and HA synthesis and accu-
mulation, we transfected human primary aortic smooth muscle cells
(AoSMCs) with an xUGDH expression plasmid pTarget-xUGDH-
sense.We also transfected the plasmid pTarget-xUGDH-antisense that
did not code for any protein as a control. We hypothesized that an
increase in UGDH activity that augments UDP-GlcUA synthesis may
increase the synthesis of HA. As shown in Fig. 3A, UGDH activity
increased in AoSMCs transfected with pTarget-xUGDH-sense,
FIGURE 1. Kinetics of xUGDH using a variable
amount of UGDH with a saturation quantity of
NAD (10mM) (A) or variable amounts ofNADwith a
saturation quantity of UGDH (5 mM) (C). Km values
for UGDH and NAD were calculated by the Lin-
eweaver-Burk method for data shown in B and D,
respectively. Thirtymicrograms of purified xUGDH
were used for each determination. The plots repre-
sent themean of three independent experiments.
FIGURE 2. Expressionof themRNAs coding for xUGDHduring embryogenesis at the
indicated hpf or days post-fertilization (dpf). Different RT-PCR cycles were used to
visualize an increase in xUGDH expression at 30 hpf. Cytoskeletal actin was used as a
reference. Bottom panel, quantitative densitometric analysis (mean S.D.) of gels from
two independent experiments. xUGDH:-actin ratio at 0 hpf was fixed as 1.
TABLE 3
Comparison of Km values (expressed in mM) of UGDH from different
species
Species Km Ref.NAD UDP-Glc
X. laevis 0.3 0.9 This work
Homo sapiens 0.35 0.1 28
Gallus gallus 0.9 0.5 33
C. elegans 0.2 0.2 13
E. coli 1 0.05 48
Streptococcus pyogenes 0.06 0.02 64
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whereas cells transfectedwith pTarget-xUGDH-antisensemaintained a
lower UGDH activity comparable with that of untransfected cells. The
increment of UGDH activity of pTarget-xUGDH-sense transfected
cells was in agreementwith that reported for othermammalian cell lines
transfected with mouse or bovine UGDH (42, 51). To verify that a
UGDH activity increase could actually increase UDP-GlcUA, we quan-
tified the UDP-GlcUA:UDP-Glc ratio by capillary zone electrophoresis
(Fig. 4). AoSMCs transfected with pTarget-xUGDH-sense, pTarget-
xUGDH-antisense vectors, or not transfected showed UDP-GlcUA:
UDP-glucose ratios of 4, 0.8, and 0.7, respectively. This clearly indicates
that the increase of UGDH activity augmented the cellular UDP-GlcUA
levels by about 4-fold with respect to control levels.
The conditioned culture media of the AoSMC cultures were col-
lected after 48 h of transfection, and their HA concentrations were
measured by FACE analysis (Fig. 3B). AoSMCs produce high levels of
HA (52, 53).Most interestingly, the HA disaccharide band derived from
106 pTarget-xUGDH-sense transfected AoSMCs was significantly
stronger than that derived from the same number of control cells (i.e.
transfected with pTarget-xUGDH-antisense or not transfected). The
UGDHactivity detected in control cells (Fig. 3A) could explain the basal
HA signals in control cell culture medium (Fig. 3B). On the other hand,
the increase of HA production in pTarget-xUGDH-sense transfected
cells could be ascribed to the augmentedUGDHactivity in those cells. A
similar result was obtained byMagee et al. (54) who discovered that the
up-regulation of UDP-glucose pyrophosphorylase stimulates HA syn-
thesis in hypertrophic chondrocyte cultures. As UDP-glucose pyro-
phosphorylase and UGDH belong to the same pathway that forms
UDP-GlcUA, it would be reasonable that the up-regulation of both of
these enzymes can increase the concentration of HA synthesis precur-
sors.Moreover, theKm values of the threeHA synthases are in the range
of the cytoplasmic concentration of UDP-sugars (55), making the activ-
ity of HA synthetic enzymes responsive to the concentrations and the
pool sizes of the cellular sugar nucleotides.
Most interestingly, densitometric quantification of the HA and the
chondroitin 4-sulfate disaccharide bands obtained from FACE analyses
revealed that chondroitin 4-sulfate synthesis did not change signifi-
cantly after the xUGDH transfections (results not shown), indicating
FIGURE 3. A, UGDH activities in AoSMC extracts transfected with pTarget-xUGDH-sense
(sense), pTarget-xUGDH-antisense (antisense), orwithoutDNA (control). xUGDHactivities
are expressed in mmol of NADHmin1 mg protein1. Transfections were done in tripli-
cate, and data are expressed as means  S.E. B, FACE analyses on conditioned culture
media of AoSMCs transfected as described above. HA, HA disaccharide; CS-0S, chon-
droitin disaccharide; CS-4S, chondroitin 4-sulfated disaccharide; CS-6S, chondroitin
6-sulfated disaccharide. The analyses were done in triplicate, and one representative
result is shown.C,quantificationofmRNAcoding forHAS1,HAS2, andHAS3byRT-PCR in
AoSMCs transfected with pTarget-xUGDH-sense (sense), pTarget-xUGDH-antisense
(antisense), or without DNA (control) after 48 h of incubation. Transfections for gene
expression analyses and the quantifications were repeated three times with identical
results both using -actin (shown) or glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (not shown) as reference genes. Unpaired Student’s t test was performed for
statistical analyses using Origin 7.5 software (Microcal Software). Gene expression is
expressed in arbitrary units.
FIGURE 4. Capillary zone electropherogram showing the UDP-Glc and UDP-GlcUA
separations. A, separation of standard (70 M) of UDP-Glu and UDP-GluA in 90 mM
borate buffer, pH 9. B, separation of extracts from AoSMC transfected with pTarget-
xUGDH-sense vector. C, separation of extracts from AoSMC transfected with pTarget-
xUGDH-antisense vector. AoSMC extracts were prepared after 48 h from transfection. In
the cellular extracts, arrows precisely indicate the UDP-Glc and UDP-GlcUA peaks.
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that theUGDHeffect was selective forHA.AlthoughUGDH is a central
enzyme in the metabolism of GAGs, it may specifically regulate HA
accumulation without altering other GAGs. In light of this specific HA
increase, we performed quantitative RT-PCR analyses on transfected
AoSMC cDNA and found that HAS2 and HAS3 mRNA levels were
up-regulated about 2-fold only in pTarget-xUGDH-sense transfected
cells, whereas HAS1 mRNA levels were unchanged (Fig. 3C). This sug-
gests that transfection of UGDH leads to an induction of HAS2 and
HAS3 gene transcription or to a stabilization of HAS2 and HAS3
mRNAs. The specific increase of HAS2 and HAS3 fits well with the
specific increase of HA in transfected AoSMCs (Fig. 3B).
The lack of increase in chondroitin sulfate may result from the fact
that precursors for this GAG must enter the Golgi apparatus by using
several UDP-sugar transporters that have been shown to possess lowKm
values for their substrates (i.e. 1–10 M) (56, 57). Although cytoplasmic
UDP-sugar precursor concentrations could directly affect the activity of
HA synthases located in the cell membrane, the UDP-sugar transport-
ers would be saturated at the cellular concentration of the UDP-sugar
precursors thereby maintaining constant concentrations inside the
Golgi apparatus and thus the constant activity of the Golgi GAG syn-
thetic enzymes. The tight relationship between UGDH activity and
GAG synthesis was also recently outlined in in vivo experiments with
fibroblast-like synovial lining cells (58) and in vitro on immature and
mature human articular cartilage explants (59), although the key impor-
tance of UGDHactivity inGAGproductionwas already suggested years
ago (60, 61).
Abrogation of Human UGDH and HA Synthesis—To demonstrate
the putative link between UGDH activity and HA synthesis, we did
siRNA experiments to reduce the endogenous UGDH in human
AoSMCs. The greatest reduction of human UGDH mRNA was
achieved by transfecting 50 M of UGDH siRNA and incubating for
48 h. In these conditions quantitative RT-PCR showed a reduction of
the human UGDH transcript of about 90% with respect to the controls
(i.e. scramble siRNA and no DNA transfected cells) (Fig. 5A). Such a
reduction of UGDH mRNA corresponded to a strong inhibition of
UGDH activity. In fact, we were not able to detect any signals in the
UGDH spectrophotometric assay used in this work indicating that the
residualUGDHactivitywas below the detection limit of the assay (result
not shown). To verify that the UGDH activity decrease could actually
reduce UDP-GlcUA content, we quantified the UDP-GlcUA:UDP-Glc
ratios (data not shown). AoSMCs transfected with UGDH siRNA,
scramble siRNA, or not transfected showed UDP-GlcUA:UDP-glucose
ratios of 0.25, 1.0, and 0.8, respectively, clearly indicating that the inhi-
bition of UGDH activity reduced the cellular UDP-GlcUA levels by
4-foldwith respect to control levels. Furthermore, the concentrations of
HA in the conditioned culture media clearly showed a corresponding
decrease (Fig. 5B) indicating that HA synthesis could be strictly regu-
lated by the availability of theUDP-sugar precursors at least inAoSMCs.
This finding supports the proposed mechanism of the 4-methylumbel-
liferone inhibition of HA synthesis; in fact, the glucuronidation of
4-methylumbelliferone by endogenous UDP-glucuronyltransferase
induces a depletion of UDP-GlcUA (62). Moreover, chondroitin 4-sul-
fate was not influenced by changing availability of the precursors (see
above).
Most interestingly, the inhibition of UGDH by siRNA did not change
the levels of transcripts coding for HAS1, HAS2, and HAS3 quantified
by quantitative RT-PCR (Fig. 5C). These data indicated that the expres-
sion of these enzymes cannot be reduced below a basal level even when
one of their substrates is strongly decreased.
GAG Determinations—To better elucidate the UGDH role in the
control of GAG synthesis, we incubated AoSMCs with [3H]glu-
cosamine to determine the GAG amount. We found that the total (i.e.
medium and cell layer) incorporated radioactivity associated with
GAGs was much higher in pTarget-xUGDH-sense transfected cells
than in the controls (i.e. 0.16 versus 0.12 cpm/cell, respectively). On the
other hand, the incorporated radioactivity associated with GAGs was
lower in siRNA against UGDH-treated cells than in the controls (0.06
versus 0.12 cpm/cell, respectively). The silencing of UGDH affected
dramatically the GAG associated to the cell layer fractions in which the
radioactivity incorporated in the GAG was undetectable. These data
support the critical role of UGDH in promoting GAG synthesis.
Moreover, we quantified the percentage of the specific GAG family in
conditionedmedium (Table 4) as well as the cell layer (Table 5) samples.
The determinations were performed counting the radioactivity in GAG
resistant to hyaluronidase SD, chondroitinase ABC, and heparinase I, II,
and III digestions as described under “Materials and Methods.” For the
percentage calculations, the total radioactivity that was digested was
considered 100%. The quantifications were done on untransfected
AoSMCs (Tables 4 and 5, control row) or transfected with pTarget-
xUGDH-sense (Tables 4 and 5, sense row) or with siRNA against
humanUGDH (Tables 4 and 5, RNAUGDH row).We found that HA is
themost produced GAG in themedium as well as in the cell layer. Most
interestingly, when we overexpressed the xUGDH, we found a signifi-
cant increase in both medium and cell-associated HA content, whereas
the synthesis of other GAGswas only slightly modified (Tables 4 and 5).
FIGURE5.A,UGDHmRNAquantificationbyRT-PCR inAoSMCs transfectedwith no siRNA
(control), a scramble siRNA (scramble), or siRNA against human UGDH (siUGDH). Trans-
fectionswere done in triplicate, and data are expressed asmeans S.E. B, FACE analyses
of conditioned culture media of siRNA AoSMCs transfected as described above (see Fig.
3 legend for disaccharides designations). The analyses were done in triplicate, and one
representative result is shown. C, quantification of mRNA coding for HAS1, HAS2, and
HAS3 by quantitative RT-PCR in AoSMCs transfected with no siRNA (control), a scramble
siRNA (scramble), or siRNA against human UGDH (siUGDH). Transfections for gene
expression analyses and the quantification were repeated three times with identical
results using both -actin (shown) or glyceraldehyde-3-phosphate dehydrogenase (not
shown) as reference genes. Gene expression is expressed in arbitrary units.
Xenopus UDP-glucose Dehydrogenase and HA Synthesis
MARCH 24, 2006•VOLUME 281•NUMBER 12 JOURNAL OF BIOLOGICAL CHEMISTRY 8261
On the other hand, when we abolished the expression of UGDH in
AoSMCby siRNA, we found a decrease ofmediumHAwithout altering
the synthesis of other released GAGs. However, in the cell layer-associ-
atedGAGs, the incorporated radioactivity was under the detection limit
(Tables 4 and 5), indicating that cell surface-associated GAGs could
have a more rapid turnover in comparison to GAGs secreted into the
medium. Most interestingly, as the sum of percentages indicated in the
table rows represents the GAG-associated radioactivity, it is notewor-
thy that in the medium fractions almost 100% of the radioactivity was
GAG-associated, and in the cell fractions the radioactivity accounted for
about 80%. This value reached about 100%whenUGDHwas induced, and
this increase (20%) was specifically caused by HA synthesis.
As observed from our previous results (Figs. 3B and 5B), we showed
thatHA is theGAG that ismore sensitive toUDP-GlcUAconcentration
inside the cytoplasm, and therefore, the cell could regulate specifically
the HA synthesis controlling the UDP-GlcUA availability.
In Vivo xUGDH Silencing—X. laevis embryos were injected bilater-
ally with xUGDH MO complementary to the 5-UTR of xUGDH
mRNA to prevent its translation. Control and xUGDH MO-treated
embryos were co-injected with mRNA coding for the green fluorescent
protein (GFP), allowing the selection of only those embryos injected in
both sides, before the subsequent analysis. Embryos treated with
xUGDH MO had severe malformations at the end of gastrulation that
led to a failure in the blastopore closure. In the subsequent developmen-
tal phases, xUGDHMO-injected embryos are not able to complete the
neurulation step correctly as the neural tube remained posteriorly
opened (90% of injected embryos n	 120) (Fig. 6A). In contrast control
embryos (injected with the same dose of the 5-mismatchMO) showed a
normal development (100% of injected embryos n	 130) (Fig. 6B). The
embryos progressively died and did not reach the tail bud stage. It has
been shown that during gastrulation, both in X. laevis and mouse
embryos, mesodermal cells enter andmove within anHA-rich environ-
ment (23, 63). Moreover, the HAS2 is expressed in the involuting mes-
oderm in X. laevis embryos (35) and appears to be critical in the
Zebrafish gastrulation process (32). Therefore, our xUGDH knock
down functional data are consistent with a role ofHA in the gastrulation
movements and suggest an important role of the xUGDH activity dur-
ing early X. laevis development.
In conclusion, we have reported the cloning of the UGDH cDNA
sequence from the amphibian X. laevis, and we found that the gene
structure and biochemical properties confirmed the data obtained in
other species.We described an up-regulation of xUGDHmRNAduring
the tail bud stage of X. laevis development that was correlated with the
elevated HA production typical of the developing embryo at this stage.
We also demonstrated a critical role of xUGDH activity in Xenopus
early development. Functional down-regulation of xUGDH, in fact,
results in early embryonic lethality. Moreover, we reported that an
increase in UGDH may be responsible for HA accumulation at least in
an in vitro cellular model. These results support the hypothesis that the
synthesis of HA requires the activation of a complex mixture of
enzymes, not only the synthetic proteins but also the enzymes involved
in metabolism of the UDP-sugar precursors.
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